What Are Prognostic Biomarkers?

A prognostic biomarker is a clinical or biological characteristic that informs possible information about a patient's health (eg, disease recurrence, disease progression, death), independent of the treatment received. They are often used to identify patients at risk of clinical events or disease progression. As prognostic biomarkers can predict the prognosis status of any patient, they have the potential to be used as enrichment factors for cancer personalized medicine.. Today, prognostic biomarkers are widely applied in the study of ocular diseases, such as age-related macular degeneration and uveal melanoma.

Fig. 1. Flowchart of potential experimental structures for prognostic caner biomarkers. (Kerr DJ, et al., 2021)

Our Services

With the development of genomics in ophthalmology and the continuous revision of the concept of individualized precision medicine, more effective prognostic biomarkers are proposed to provide more relevant information for clinical decision-making. As one of the industry leaders in ophthalmology, Ace Therapeutics' capabilities in ophthalmic drug development include biomarker discovery, characterization, validation, and quantitative analysis of primary cells and disease tissues, pharmacodynamics, and disease models. With professional technical scientists and rich experience, Ace Therapeutics has become the preferred partner for our global customers to conduct prognostic biomarker research. With a range of effective ocular prognostic biomarker identification and analysis solutions, you can trust us to meet these scientific challenges.

Explore Our Ocular Prognostic Biomarker Service Strategies

• Flow Cytometry

Flow cytometry is a technique used to detect and measure the physical and physiological characteristics of a population of cells or particles. Tens of thousands of cells can be examined quickly and the data collected is processed by a computer. The flow cytometry team at Ace Therapeutics can support all aspects of analysis for the identification of ocular prognostic biomarkers. Our team is experienced in measuring a wide range of cells including T cells, B cells, macrophages/monocytes, basophils, neutrophils, dendritic cells and cell-derived granules. Our experts are available to help and advise you on what you need to know.

• High-Throughput Microarray Techniques

Microarray technology is capable of simultaneously determining the relative expression of tens of thousands of proteins or genes, resulting in very large databases. Identifying potential eye cancer biomarkers is one of the most critical goals of microarray analysis. Ace Therapeutics' team of experts in microarray technology provides highly customized protein microarrays and gene expression microarrays for ocular prognostic biomarkers discovery and analysis, thus meeting our customers' needs for basic, applied and clinical research.

• Genomic Sequencing Techniques

Genome-based prognostic biomarkers are also available for a variety of ocular cancer types. Among them, high-throughput NGS technology enables us to dig deeper into prognostic biomarkers through the analysis of omics data. Scientists at Ace Therapeutics are using gene sequencing technology to build robust prognostic models for specific types of cancer. In addition, functional analyses of prognostic genes can be performed. We have extensive experience in genetic and epigenetic genetic analysis to analyse and study the association between identified genetic biomarkers and their associated protein-synthesising pathways.

Our Experience

• Translated clinical biomarker analyses for multiple client projects.
• Provide a variety of in vitro living animal models, and develop customized models according to customers' projects.
• The scope of services covers a variety of diseases in ophthalmology.
• The support of multiple omics technologies.
• Advanced analytics platform.
• Flow cytometry

Ace Therapeutics has built a team of experienced scientists with facilities and processes specifically designed to meet every challenging requirement in ocular prognostic biomarker discovery. Our many years of experience and flexible service options help us provide fast and reliable support for customers at any stage of project development. If you are interested in our services, please feel free to contact us.

References

1. Kerr DJ, Yang L. Personalising cancer medicine with prognostic markers. EBioMedicine. 2021;72:103577.
2. Lamas NJ, Martel A, Nahon-Estève S, et al. Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions. Cancers (Basel). 2021;25;14(1):96.
3. Ly A, Yapp M, Nivison-Smith L, et al. Developing prognostic biomarkers in intermediate age-related macular degeneration: their clinical use in predicting progression. Clin Exp Optom. 2018;101(2):172-181.

• Omics-Based Ocular Biomarker Discovery and Analysis Services
• Ocular Matrix Biomarker Discovery and Analysis Services
• Ocular Imaging Biomarker Services
• Ocular Predictive Biomarker Identification Services
• Ocular Transformational Biomarker Services
• Ocular Pharmacodynamic Biomarker Services
• Custom Ocular Biomarker Development Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit